Last reviewed · How we verify
NCT05243251
Olanzapine Anorexia Cachexia
Phase 3 trial testing Olanzapine 5 MG in Anorexia in 164 participants. Completed in 14 December 2022.
21 November 2022
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 164 |
| Start date | 25 December 2021 |
| Primary completion | 21 November 2022 |
| Estimated completion | 14 December 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Olanzapine 5 MG — full drug profile →
- Placebo
Conditions studied
- Anorexia — all drugs for Anorexia →
Sponsor
Cairo University
Who can join
18 and older, any sex, with Anorexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
164 patients will be recruited..Adult patients diagnosed with incurable solid tumors and CCAA who presented to Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) - Kasr Al-Ainy School of Medicine - Cairo University will be randomly distributed into 1:1..82 will receive Olanzapine 5 mg daily at night and 82 patients will receive placebo for 4 weeks. Primary outcome is Change in loss of appetite score from day 0 to day 7 of treatment and secondary outcomes change in body weight, change in loss of appetite score..and change in quality of life
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer cachexia: molecular mechanisms and treatment strategies.
Setiawan T, Sari IN, Wijaya YT, Julianto NM, et al · · 2023 · cited 176× · PMID 37217930 · DOI 10.1186/s13045-023-01454-0 -
Mechanisms and pharmacotherapy of cancer cachexia-associated anorexia.
Sato R, da Fonseca GWP, das Neves W, von Haehling S. · · 2025 · cited 14× · PMID 39776294 · DOI 10.1002/prp2.70031 -
Cancer cachexia: molecular basis and therapeutic advances.
Tan Y, Xue R, Pan Y, He Z, et al · · 2026 · cited 3× · PMID 41526343 · DOI 10.1038/s41392-025-02331-7 -
The Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia
Del Fabbro E, Pandey S. · · 2026
Verify or expand the search:
- PubMed search for NCT05243251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olanzapine 5 MG
Trials testing the same drug.
- NCT06517199 — Olanzapine for Cancer Related Anorexia-cachexia Syndrome · Phase 3 · recruiting
- NCT04535141 — Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants · Phase 3 · completed
Other recruiting trials for Anorexia
Currently open trials in the same condition.
- NCT06517199 — Olanzapine for Cancer Related Anorexia-cachexia Syndrome · Phase 3 · recruiting
- NCT04939090 — Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients · Phase 3 · active not recruiting
- NCT03637816 — Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer · Phase 2, PHASE3 · active not recruiting
- NCT00488072 — Effects of Mirtazapine on Appetite in Advanced Cancer Patients · Phase 2 · active not recruiting
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05243251 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05243251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing